User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Drug insight : panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer

Primary tabs

Mano, Max S. [UCL] Humblet, Yves [UCL]

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in Western countries. Despite the progress achieved with the introduction of new cytotoxic agents, CRC recurrence rates for patients with resected stage II and/or stage III disease remain higher than 20%. Furthermore, for patients diagnosed with metastatic CRC, the median survival time remains below 2 years and cure is often an elusive goal. These data highlight the need for more-effective systemic therapies. The EGFR is frequently overexpressed in CRC and has been associated with the malignant phenotype. Numerous clinical trials are now investigating the role of EGFR-targeted agents in CRC and have produced some encouraging results. Panitumumab is a fully human IgG(2) monoclonal antibody that in a randomized phase III trial was shown to increase efficacy when added to best supportive care in patients with chemotherapy-refractory metastatic CRC. In phase I-III trials, panitumumab was safe and well tolerated, with most of its adverse effects related to some form of skin toxic effect. Early studies assessing the safety and efficacy of panitumumab alongside chemotherapy have also yielded promising results, and this combination is now being investigated in the first-line and second-line settings in randomized clinical trials.

Document type Article de périodique (Journal article) – Synthèse de littérature – Journal Article, Review
Publication date 2008
Language Anglais
Journal information "Nature Clinical Practice Oncology" - Vol. 5, no. 7, p. 415-425 (2008)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) London)
issn 1743-4254
e-issn 1743-4262
Publication status Publié
Affiliations UCL - MD/MINT - Département de médecine interne
UCL - (SLuc) Unité d'oncologie médicale
MESH Subject Treatment Outcome ; Receptor, Epidermal Growth Factor - drug effects ; Humans ; Drug Therapy, Combination ; Colorectal Neoplasms - drug therapy ; Clinical Trials as Topic ; Biological Markers ; Antineoplastic Agents - pharmacology - therapeutic use ; Antibodies, Monoclonal - pharmacology - therapeutic use
Keywords antibody ; chemotherapy ; colorectal cancer ; EGFR ; panitumumab
Links
  1. Douillard JY, Lancet, 355, 1041 (2000)
  2. de Gramont A, J Clin Oncol, 18, 2938 (2000)
  3. Twelves C, Eur J Cancer, 38, S15 (2002)
  4. Twelves C, N Engl J Med, 352, 2696 (2005)
  5. de Gramont A, J Clin Oncol, 23, a16S (2005)
  6. Wolmark N, J Clin Oncol, 23, a16S (2005)
  7. Landis SH, CA Cancer J Clin, 49, 8 (1999)
  8. Tournigand C, J Clin Oncol, 22, 229 (2004)
  9. Colucci G, J Clin Oncol, 23, 4866 (2005)
  10. Hurwitz H, N Engl J Med, 350, 2335 (2004)
  11. Saltz L, J Clin Oncol, 25, a18S (2007)
  12. Porebska I, Tumour Biol, 21, 105 (2000)
  13. Spano JP, Ann Oncol, 16, 189 (2005)
  14. Carpenter G, J Biol Chem, 265, 7709 (1990)
  15. Hemming AW, J Surg Oncol, 51, 147 (1992)
  16. Mayer A, Cancer, 71, 2454 (1993)
  17. Aaronson SA, Science, 254, 1146 (1991)
  18. Ciardiello F, Clin Cancer Res, 7, 2958 (2001)
  19. Sako Y, Nat Cell Biol, 2, 168 (2000)
  20. Spano JP, Ann Oncol, 16, 102 (2005)
  21. McKay JA, Eur J Cancer, 38, 2258 (2002)
  22. Yang XD, Cancer Res, 59, 1236 (1999)
  23. Yang XD, Crit Rev Oncol Hematol, 38, 17 (2001)
  24. Foon Kenneth A, Yang Xiao-Dong, Weiner Louis M, Belldegrun Arie S, Figlin Robert A, Crawford Jeffrey, Rowinsky Eric K, Dutcher Janice P, Vogelzang Nicholas J, Gollub Jared, Thompson John A, Schwartz Garry, Bukowski Ronald M, Roskos Lorin K, Schwab Gisela M, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody, 10.1016/j.ijrobp.2003.09.098
  25. Lynch DH, Semin Oncol, 29, S47 (2002)
  26. Iannello A, Cancer Metastasis Rev, 24, 487 (2005)
  27. Figlin RA, Proc Am Soc Clin Oncol, 21, 10a (2002)
  28. Cunningham D, N Engl J Med, 351, 337 (2004)
  29. Arends R, J Clin Oncol, 23, a16S (2005)
  30. Weiner LM, J Clin Oncol, 23, a16S (2005)
  31. Malik I, J Clin Oncol, 23, a16S (2005)
  32. Bardia Aditya, Loprinzi Charles L., Goetz Matthew P., Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series, 10.1200/jco.2006.06.1143
  33. Schwartzberg L, J Clin Oncol, 25, a18S (2007)
  34. Hecht J, Ann Oncol, 18, aSvii21 (2007)
  35. Van Cutsem E, J Clin Oncol, 25, 1658 (2007)
  36. Giusti RM, Oncologist, 12, 577 (2007)
  37. Segaert S, Ann Oncol, 16, 1425 (2005)
  38. Hendlisz A, Ann Oncol, 17, 284 (2006)
  39. Humblet Y, J Clin Oncol, 25, a18S (2007)
  40. Tejpar S, Lancet Oncol, 8, 387 (2007)
  41. Helbling D, Ann Oncol, 18, 963 (2007)
  42. Hotta K, Cancer J, 11, 417 (2005)
  43. Saltz LB, J Clin Oncol, 22, 1201 (2004)
  44. Saltz L, Clin Colorectal Cancer, 5, S98 (2005)
  45. Chung KY, J Clin Oncol, 23, 1803 (2005)
  46. Hebbar M, Anticancer Drugs, 17, 855 (2006)
  47. Lenz HJ, J Clin Oncol, 24, 4914 (2006)
  48. Cappuzzo F, J Natl Cancer Inst, 97, 643 (2005)
  49. Takano T, J Clin Oncol, 23, 6829 (2005)
  50. Moroni M, Lancet Oncol, 6, 279 (2005)
  51. Lievre A, Cancer Res, 66, 3992 (2006)
  52. Vallbohmer D, J Clin Oncol, 23, 3536 (2005)
  53. Vincenzi B, J Clin Oncol, 24, 1957 (2006)
  54. Eberhard DA, J Clin Oncol, 23, 5900 (2005)
  55. Lynch TJ, N Engl J Med, 350, 2129 (2004)
  56. De Roock W, Proc Am Soc Clin Oncol, 25, a18s (2007)
  57. Shia J, Mod Pathol, 18, 1350 (2005)
  58. Sauer T, Histopathology, 47, 560 (2005)
Bibliographic reference Mano, Max S. ; Humblet, Yves. Drug insight : panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. In: Nature Clinical Practice Oncology, Vol. 5, no. 7, p. 415-425 (2008)
Permanent URL http://hdl.handle.net/2078.1/36512